TARS (STOCKS)
Tarsus Pharmaceuticals, Inc. Common Stock
$61.850000
-0.100000 (-0.16%)
Prev close: $61.950000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Bobak Azamian
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,658.02M
- Employees
- 323
- P/E (TTM)
- -54.57
- P/B (TTM)
- 7.64
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.16 | $-0.38 | +0.2178 | +57.65% |
|
Dec 2025 (Q4)
|
$-0.20 | $-0.10 | -0.1030 | -106.19% |
|
Sep 2025 (Q3)
|
$-0.30 | $-0.36 | +0.0574 | +16.06% |
|
Jun 2025 (Q2)
|
$-0.48 | $-0.41 | -0.0724 | -17.76% |
Financial Statements
| Revenues | $535.08M |
| Benefits Costs and Expenses | $579.28M |
| Costs And Expenses | $585.89M |
| Nonoperating Income/Loss | $6.96M |
| Operating Expenses | $576.49M |
| Selling, General, and Administrative Expenses | $478.76M |
| Research and Development | $72.26M |
| Operating Income/Loss | -$50.81M |
| Income/Loss From Continuing Operations After Tax | -$48.27M |
| Income/Loss From Continuing Operations Before Tax | -$42.36M |
| Income Tax Expense/Benefit | $4.41M |
| Net Income/Loss | -$48.27M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$48.27M |
| Net Income/Loss Available To Common Stockholders, Basic | -$48.27M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.13 |
| Diluted Earnings Per Share | -$1.13 |
| Basic Average Shares | 128,252,129 |
| Diluted Average Shares | 128,252,129 |
| Assets | $581.14M |
| Current Assets | $537.23M |
| Inventory | $4.57M |
| Prepaid Expenses | $26.72M |
| Other Current Assets | $505.94M |
| Noncurrent Assets | $43.91M |
| Fixed Assets | $17.67M |
| Intangible Assets | $7.13M |
| Other Non-current Assets | $19.11M |
| Liabilities | $232.18M |
| Current Liabilities | $143.51M |
| Accounts Payable | $24.13M |
| Wages | $8.53M |
| Other Current Liabilities | $110.85M |
| Noncurrent Liabilities | $88.68M |
| Long-term Debt | $72.60M |
| Other Non-current Liabilities | $16.08M |
| Equity | $348.95M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $348.95M |
| Liabilities And Equity | $581.14M |
| Net Cash Flow From Operating Activities | -$16.45M |
| Net Cash Flow From Operating Activities, Continuing | -$16.45M |
| Net Cash Flow From Investing Activities | -$65.74M |
| Net Cash Flow From Investing Activities, Continuing | -$65.74M |
| Net Cash Flow From Financing Activities | $8.03M |
| Net Cash Flow From Financing Activities, Continuing | $8.03M |
| Net Cash Flow | -$74.16M |
| Net Cash Flow, Continuing | -$74.16M |
| Comprehensive Income/Loss | -$48.65M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$48.65M |
| Other Comprehensive Income/Loss | $57.66M |